Ste24p mediates proteolysis of both isoprenylated and non-prenylated oligopeptides

Emily R. Hildebrandt¹, Buenafe T. Arachea², Michael C. Wiener², and Walter K. Schmidt¹

¹Department of Biochemistry and Molecular Biology, The University of Georgia, Athens, GA 30602, USA
²Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA, 22908, USA

Running title: Oligopeptidase activity of Ste24p

Address correspondence to: Walter K. Schmidt, Ph.D., A416 Life Sciences Building, 120 Green St., Athens, GA 30602. Phone: (706) 583-8241; Fax: (706) 542-1738; E-mail: wschmidt@bmb.uga.edu

Keywords: enzyme kinetics; membrane enzyme; metalloprotease; peptidase; protein isoprenylation.
The distal cleavage sites of these proteins lack sequence similarity and vary in distance from the isoprenylated cysteine (14 and 25 residues, respectively).

Orthologs of Rce1p and Ste24p are found across diverse species, including bacteria, and in all cases, the proteases are membrane proteins. The structure of Methanococcus maripaludis Rce1p (MmRce1p) reveals a hydrophobic substrate-binding pocket that is solvent exposed and a novel aspartate-histidine dependent active site (16). The structure is consistent with mutational studies identifying these residues as critical for activity of Rce1p from various eukaryotic species (4,5,17). Despite the absence of identified isoprenylated proteins in prokaryotes, MmRce1p cleaves a farnesylated substrate in vitro (18,19).

Structures of yeast and human Ste24p reveal this protease family to form a large fully enclosed chamber that contains a zinc-dependent active site (6,7). The chambered active site is fully protected from its membrane surroundings, leaving open the question of how substrates gain access. A chambered active site, although unusual, exists in other metalloprotease families, notably the M16A family of soluble zinc-dependent metalloproteases (20,21). The Ste24p chamber (~14,000 Å³) has similar dimensions as the typical M16A protease chamber (~16,000 Å³). Interestingly, both protease families possess extended β-strand secondary structure near the active site that, in the case of M16A proteases, is responsible for orienting substrates (Figure 8) (20). The human M16A protease IDE cleaves numerous small peptides and has been implicated in the clearance of neurotoxic Aβ peptides and other amyloidogenic peptides (22-26). The yeast M16A protease Ste23p also cleaves amyloidogenic peptides (27). Coincidentally, the yeast M16A proteases Ax1lp and Ste23p are both involved in a-factor production (28).

Ste24p is found in all domains of life. In humans, loss of Ste24p function is associated with defective deposition of nuclear lamin A and is associated with several diseases: Hutchinson-Gilford progeria, mandibuloacral dysplasia, and generalized lipodystrophy (29). In Drosophila, Ste24p is implicated in regulation of cytoskeletal remodeling associated with spermatid maturation and a germ-cell migration event that is posited to involve production of a yet to be identified secreted, isoprenylated signaling molecule (30,31). In yeast, where the precursor of the a-factor mating pheromone is the best-described Ste24p substrate to date, other substrates are highly likely. Their existence is inferred from the observation that Ste24p is expressed at high levels (i.e. among the top 10% most abundant proteins in yeast) and in cells that do not produce a-factor (i.e., MATα and diploid cells) (32,33).

In this study, we have taken cues from substrate competition experiments and the similarity in structures between Ste24p and M16A family enzymes to more deeply explore the substrate profile of Ste24p. We have determined that Ste24p cleaves non-prenylated peptides, including the Aβ peptide. By contrast, Rce1p does not cleave these substrates. Our findings firmly establish that Ste24p has a broader substrate specificity than previously recognized. These findings provide potential insight into the biological function of Ste24p and suggest that its major biological role may not be as a CaaX protease.

**EXPERIMENTAL PROCEDURES**

*Substrates, competitors, and other reagents -* Peptides and reagents were purchased from commercial sources: Aβ 1-40 (rPeptide, Bogart, GA); a-factor, human recombinant insulin, bovine insulin B-chain, and trans,trans-farnesyl bromide (Sigma-Aldrich, St. Louis, MO); carboxymethylated porcine insulin A and B-chains (Schwarz/Mann); 15-mers based on a-factor YIKGVFWDPCAVIA and YIKGVFWDPC(farnesyl)VIA (California Peptide, Napa, CA); Zymolyase 100T (Cape Cod Inc., East Falmouth, MA); E. coli polar lipid (Avanti Polar Lipids, Alabaster, AL). The fluorescent, farnesylated 9-mer peptides ABZ-KSKTKC(farnesyl)VIK and ABZ-KSKTKC(farnesyl)K1IM were purchased from Anaspec (San Jose, CA); K1 denoted as Q1 in previous publications (4,34). The fluorescent, non-prenylated, peptides based on a-factor (ABZ-SEKKDYIYIKGKVY-NITRO, M16A reporter) and human Aβ (DAEFRHDSGYEVHHQK(DABCYLLVFFAE)EDANS-DVG SNK) were purchased from CHI Scientific (Maynard, MA); Y-NITRO denoted as nitroY in previous publications (27,35). Trans,trans-farnesyl bromide was prepared as 100 mM stock in DMSO. E. coli polar lipid was prepared at 50 mg/ml in H2O and stored under nitrogen gas. Fluorescent isoprenylated and non-prenylated peptides were prepared as 1 mM stocks in 4% DMSO. Isoprenylated and non-prenylated a-factor-based peptides were prepared as 1 mM stocks in methanol. Non-prenylated Aβ 1-40, and insulin-based peptides were prepared as 4 mg/ml stocks in 100% DMSO. Prior to use, Aβ 1-40 and insulin-based peptides were incubated for 20 minutes in a water bath sonicator and heated at 65 °C for 5 minutes.

*Plasmids and yeast strains -* Plasmid transformed versions of S. cerevisiae strain SM3614
Oligopeptidase activity of Ste24p

(MATa trp1 leu2 ura3 his4 can1 rce1::TRP1 ste24::LEU2) were created using published methods (2). Previously described plasmids used were: pRS316 (CEN URA3) (36); pSM1282 (2µ URA3 PPGK-HIS-HA-ScSTE24) (2); pWS804 (p17-HIS-RnIDE-M42-L109') (27); pWS335 (2µ URA3 PPGK-HIS-HA-HsRce1Δ22) and pWS479 (2µ URA3 PPGK-ScRCE1-HA) (4). pWS1275 (2µ URA3 PPGK-HA-HsSTE24) was created by PCR-directed, plasmid-based recombination (37). The PCR fragment containing HA-HsSTE24 was derived from pSM1468 (CEN URA3 HsSTE24) using appropriately designed PCR primers (2); the recipient vector pWS767 (2µ URA3 PPGK-HIS-HA-TbSTE24) was digested using EcoRI and MluI before use (5).

Proteases - Rat IDE was expressed in BL21 DE3 E. coli from plasmid pWS804 and was purified as described previously (38). Saccharomyces mikatae Ste24p (SmSte24p) was purified as previously described (6). Membranes used as a source of protease activities were prepared from yeast strains expressing Rce1p or Ste24p according to our previously reported methods (4,5,39). The yeast strains were derived by transforming SM3614 with the desired over-expression plasmid: vector (pRS316); ScSte24p (pSM1282); HsRce1 (pWS335); ScRce1p (pWS479); pWS1275 (HsSTE24). Isolated membranes were stored at -80 °C as 1 mg/ml total protein stocks in Lysis Buffer (50 mM Tris, pH 7.5, 0.2 M sorbitol, 1 mM EDTA, 0.2% NaN3) containing protease inhibitors (1 µg/ml each chymostatin, leupeptin, pepstatin, and aprotinin; 1 µM PMSF).

In vitro fluorescence-based proteolysis assay - A fluorescence-based assay was used to monitor protease-dependent cleavage of internally quenched fluorogenic peptide substrates (4,40,41). In general, the assay involved mixing 50 µL of substrate with 50 µL of yeast membrane suspension or purified protease, where each individual component was prepared at twice the intended final concentration. The individual components were assembled in a 96-well microtiter plate (Corning 3631), and fluorescence measured at regular intervals over a 60-min time course at 30 °C using a Bio-Tek Synergy fluorometer equipped with a 320/420 nm excitation/emission filter set. For the Aβ1-28 peptide a 320/485 nm filter set was used. Samples were typically analyzed in duplicate.

Unless otherwise noted, the substrate components were prepared by dilution of stocks to 40 µM with HM buffer (100 mM HEPES pH 7.5, 10 mM MgCl2). The enzyme components were prepared by diluting membrane stocks to 0.2 mg/ml (total protein concentration determined by Bradford Protein Assay) with HM-BSA buffer (100 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mg/ml BSA), purified rat IDE to 0.08 mg/ml (measured using A280nm and a calculated extinction coefficient of 113570 M⁻¹cm⁻¹) with HM-BSA buffer, and purified SmSte24p (measured using A280nm and a calculated extinction coefficient of 58,790 M⁻¹cm⁻¹) to 0.08 mg/ml in HM buffer. Studies involving purified SmSte24p included added E. coli polar lipid (125 or 500 µg/ml) as a buffer component, except for mass spectroscopy studies (see below). For competition assays, substrate and competitor were premixed at appropriate molar ratios in the microtiter plate prior to the addition of enzyme. For K_M determinations, a range of substrate concentration was used (0-200 µM).

Activity and kinetic analyses – For all fluorescence-based assays, data were graphed using Microsoft Excel. Initial linear slopes (rfu/min) were determined using a time window that was manually optimized for each condition (usually minutes 1-10).

To obtain percent activity, values were calculated relative to an appropriate control (i.e. solvent, DMSO, or methanol-treated). When DTT and iodoacetamide were used in reactions, insulin or DMSO was pre-incubated for 15 min at room temperature with a 3-fold molar excess of DTT followed by quenching for 15 min with 2-fold molar excess of iodoacetamide relative to DTT. The data for each experimental condition were generally collected in replicate, often across two or more independent experiments. See figure legends for details.

To obtain reaction rates and other kinetic parameters, rate values (rfu/min) values were converted to product amounts per minute (µmol/min) by referencing two standard curves (27,35,42). First, the amount of fluorescence observed was corrected for intermolecular quenching using standard curves for fluorophore alone and a 1:1 mixture of fluorophore and quencher pair (see Figure 9). This was necessary at high substrate concentration but not generally needed for comparative activity assays at lower concentrations. Second, the corrected amount of fluorescent product was converted to a mole amount of product using a fluorophore-only standard curve. Kinetic parameters (i.e. K_M, V_max) were extracted from a curve fit by nonlinear regression methods (Prism 6.0 GraphPad Software Inc.).

Mass spectroscopy – Generally, cleavage products were prepared by incubating peptides with or without purified SmSte24p in Buffer MS (40 mM HEPES, pH 7.5, 250 mM NaCl 1.3% glycerol, 0.01% C12E7) for 12 hours at room temperature, stopping reactions with EDTA (12 mM), then analyzing products by LC-MS. Specifically, M16A reporter ABZ-SEKKDNYI1KGVY_NITRO (25 µM), K-Ras4b reporter ABZ-KSKTKC(farnesyl)VIK_B (25 µM), and...
carboxymethylated insulin B-chain (68 µM) were incubated with 18 µg/ml, 20 µg/ml and 50 µg/ml, respectively, of purified SmSTE24p. For the fluorescent peptides, these reaction conditions yielded 45-85% sample cleavage as judged by comparing the fluorescence of SmSte24p-treated samples with that of trypsin-treated samples prepared in parallel; the extent of insulin B-chain cleavage was not determined. Products were analyzed by LC-MS using appropriate acetoni trile/trifluoroacetic acid gradients and a Kromasil C-18 column (Keystone Scientific/ThermoScientific) with mass spectra being acquired using a mass spectrometer with ESI source (i.e. Waters Micromass Q-Tof Micro or Bruker Esquire 3000 Plus ion trap). Peptide masses within the spectra were identified manually with the aid of FindPept (http://web.expasy.org/findpept/).

SDS-PAGE analysis of peptide degradation - Reactions were assembled in HM buffer to contain purified SmSte24p (0.05 mg/ml) or purified rat IDE (0.05 mg/ml), E. coli lipid (0.6 mg/ml), and a peptide substrate. The peptide substrates evaluated were: human insulin (54 µM); porcine insulin B-chain (70 µM); human Aβ 1-40 (60 µM). Reactions were incubated 12 hours at 30 °C, quenched with EDTA (12 mM), and samples analyzed by 18% SDS-PAGE and staining with Coomassie R250.

RESULTS

Rce1p and Ste24p differ in their requirements for an isoprenylated substrate - An expected unifying feature of the Rce1p and Ste24p CaaX proteases is that both recognize the isoprenylated CaaX sequence as a specific recognition determinant. In fact, the lack of an isoprenyl group was the reason given for the ‘misalignment’ of the non-prenylated CSIM tetrapeptide in the co-crystal structure of human Ste24p (i.e. predicted cleavage at P1’-P2’ rather than P1-P1’) (7). To initially test this “Standard Model” of substrate recognition for yeast Rce1p and Ste24p, we performed competition assays involving isoprenylated reporter substrates in combination with isoprenylated and non-prenylated peptides (Figure 1A). The reporters were internally quenched fluorogenic nonapeptides based on the farnesylated C-terminus of K-Ras4b (i.e. K-Ras4b reporter) while the competitors were based on the a-factor sequence (34). ER membranes enriched from yeast were used as the source of activity; both proteases are ER-associated membrane proteins (8). The yeast strains used for membrane isolation were designed to overexpress either Rce1p or Ste24p in the absence of the other CaaX protease.

The Standard Model predicts that cleavage of the K-Ras4b reporter by Rce1p and Ste24p would be diminished by the presence of competing isoprenylated CaaX peptides. Indeed, we observed this to be the case for both proteases. Cleavage of the K-Ras4b reporter was significantly reduced when a competing non-fluorescent farnesylated substrate (C(f)VIA) was present in 2-fold molar excess (Figure 1B-C). The Standard Model also predicts that cleavage of the K-Ras4b reporter by Rce1p and Ste24p would be relatively unaffected by competing peptides lacking either the CaaX motif or isoprenoid moiety. Indeed for Rce1p, such peptides had only a minor impact on cleavage of the K-Ras4b reporter. Significant activity was still observed in the presence of mature a-factor (an isoprenylated and carboxymethylated peptide lacking a CaaX motif) and a non-prenylated peptide matching the pre-processed form of the a-factor sequence that contains a CaaX motif (CVIA). These results indicate that optimal substrate recognition by Rce1p relies on both the isoprenoid and aaX features of substrates. For Ste24p, however, we unexpectedly observed that all three peptides had a significant negative impact on cleavage of the K-Ras4b reporter. The effective competition by these peptides suggests that a farnesylated CaaX sequence is a minimal recognition determinant for Rce1p but not Ste24p.

Ste24p cleaves a peptide modeled on the M16A protease cleavage site in the a-factor precursor – We interpreted the findings of our competition experiments to indicate that non-prenylated peptides can influence the activity of Ste24p. Due to experimental design, however, we could not establish whether non-prenylated peptides were actually being cleaved or binding non-productively. We did note, however, that Quigley et al reported, but did not discuss, cleavage of a non-prenylated peptide based on the lamin A precursor (7). To probe this issue further, we sought to directly investigate whether Ste24p could cleave non-prenylated substrates.

Our choice of non-prenylated substrates to evaluate was directed by shared structural and functional similarities between membrane-bound Ste24p and soluble M16A proteases. Both are zinc-dependent metalloproteases with active sites sequestered in a large chamber. Both proteases have a β-sheet domain near the site of peptide hydrolysis that properly positions substrates for cleavage (6,7,20); this structural feature is not observed in Rce1p family members (Figure 8) (16). Moreover, yeast Ste24p and M16A proteases (Ste23p, Axl1p) cleave the a-factor precursor at different sites that are each distal from the CaaX motif, indicating that they can cleave non-prenylated regions of the same peptide, albeit at different locations (27,28,32). M16A proteases cleave...
a variety of small peptides, potentially up to ~80 amino acids in length (20,21,43). The maximum substrate size is limited by the volume of the M16A protease chamber (~16,000 Å³). The Ste24p chamber has a similar sized chamber (~14,000 Å³) (6).

For studies of yeast M16A proteases, we previously developed a reporter peptide (M16A reporter) that contains the site within a-factor that is normally cleaved by Ax11p and Ste23p (Figure 2A) (27,28). The mammalian M16A protease IDE also cleaves this reporter (Figure 2B) (27,35). Yeast Ste24p readily cleaved the M16A reporter, whereas Rce1p could not. As observed with the farnesylated K-Ras4b reporter, cleavage of the M16A reporter was significantly reduced under mixed-substrate conditions involving both prenylated and non-prenylated peptides based on a-factor (Figure 2C).

The shape of Ste24p progress curves depends on substrate - To assess the relative cleavage efficiency of both isoprenylated and non-prenylated peptides by Ste24p, we determined kinetic parameters (Figure 3A-C). This analysis revealed that the K_M of yeast Ste24p for the farnesylated K-Ras4b reporter (16.4 µM) was similar to our previously published values (34); the slightly higher K_M value reported here is the consequence of normalizing for intermolecular quenching, which was not done in prior studies. The data fit well (R^2 = 0.98) to an allosteric sigmoidal model, with a Hill coefficient of 1.8, suggestive of positive cooperativity. By contrast, the K_M of yeast Ste24p for the non-prenylated M16A reporter was much higher (i.e. 112.5 µM), the V_max was substantially higher (1.66 µM/min vs. 0.53 µM/min), and data fit to standard Michaelis-Menten kinetics. Taken together, the data suggest that Ste24p recruits the prenylated peptide better than the non-prenylated peptide, but can efficiently cleave the non-prenylated peptide once acquired. Curiously, both Ste24p and rat IDE have a high K_M for the non-prenylated M16A reporter under the same reaction conditions.

Next we considered a possible underlying reason for the non-Michaelis-Menten kinetics observed for Ste24p with the farnesylated K-Ras4b reporter. Such behavior is often associated with positive cooperativity, which can result from several scenarios. Subunit cooperativity (i.e. multimerization) is a common reason. However, purified recombinant yeast and human Ste24p are both monomeric in solution, and there is no evidence of functionally-relevant oligomerization in crystals used to determine their structures (6,7). Kinetic cooperativity due to enzyme hysteresis (i.e. a slow, substrate-induced isomerization of the enzyme) is also possible, but this would be accompanied by a lag in enzyme activation time, which was not readily observed in Ste24p progress curves. Multiple substrate binding sites can also lead to sigmoidal kinetics, so it is possible that Ste24p has separate peptide and isoprenoid binding sites that act cooperatively. This seems unlikely given that Ste24p activity was largely unaffected by the presence of excess farnesyl (Figure 3D). By comparison, Rce1p activity was significantly reduced. Curves resembling, but not indicative, of cooperative kinetics are also observed when substrates bind both specific and non-specific sites (44). Since lipidation can increase a protein or peptide’s membrane binding affinity, the lipid bilayer surrounding Ste24p in membranes could be acting as an abundant, low-affinity binding site for the substrate. To test this possibility, we measured the activity of membrane-enriched Ste24p after mixing with increasing amounts of membrane devoid of both Rce1p and Ste24p (rce1∆ ste24∆). We observed increasing sequestration of the farnesylated substrate into an inactive pool (Figure 4). By contrast, no sequestration was observed for the non-prenylated substrate.

Ste24p cleaves a peptide modeled on Aβ - M16A proteases are perhaps best known for their ability to cleave small peptides that adopt β-strand secondary structure when positioned in the M16A active site. Biomedically relevant substrates include the Aβ peptides and insulin chains. We thus challenged Ste24p and Rce1p to cleave an internally quenched fluorogenic peptide based on Aβ that includes a cleavage site recognized by IDE (Phe-Phe) (45). This reporter is cleaved by rat, worm and human IDE (35). Both yeast and human Ste24p cleaved the reporter, whereas yeast and human Rce1p did not (Figure 5). As observed for the M16A reporter, a hyperbolic kinetic curve was observed with the Aβ reporter. The K_M for Ste24p (K_M 52.3 µM) was approximately 3x lower than the reported value for rat IDE against this same peptide (i.e. K_M 142.3 µM), albeit under using different buffering conditions (35). Nonetheless, these results indicate that Ste24p cleaves the Aβ reporter somewhere among the 6 peptide bonds that exist between the fluorophore and quencher (i.e. FRET pair).

Ste24p cleaves biological peptides - Our investigations involving FRET reporters indicated that Ste24p can cleave non-prenylated peptides. Because these modified peptides may have altered substrate properties, we investigated whether Ste24p could cleave unadulterated substrates of IDE. Through competition assays, we observed that whole insulin minimally reduced the activities of both Ste24p and Rce1p against their farnesylated K-Ras4b reporters. As expected, insulin had a much larger impact on IDE
cleavage of the M16A reporter (Figure 6A). We next evaluated the competitive nature of individual insulin chains to address the possibility that the size and/or constrained conformation of insulin might prevent its interaction with Ste24p. We observed that both insulin A and B-chains reduced Ste24p activity to a similar extent (Figure 6B); minimal effects on activity were observed for Rce1p in the presence of insulin chains in parallel studies.\textsuperscript{4} With increasing amounts of competing insulin B-chain in Ste24p reactions, we observed a concomitant increase in $K_M$ and no change in $V_{\text{max}}$ (Table 1), indicative of competitive inhibition. A mixture of unlinked insulin A and B chains also competed for Ste24p activity; the mixture was prepared by DTT/iodoacetamide treatment of whole insulin. These results suggest that, by comparison to insulin chains, the size and/or conformation of whole insulin might indeed influence its availability as a competitor. Unfortunately, these two possibilities are not separable by our experimental approach. Nonetheless, they demonstrate a critical difference between Ste24p and IDE. Ste24p is unlikely to bind and therefore cleave whole insulin, whereas IDE has this ability.

For a more direct assessment of the ability of Ste24p to cleave IDE substrates, we used purified components and a gel-based assay to examine products formed after \textit{in vitro} cleavage reactions. Initial experiments using purified SmSte24p revealed little if any cleavage of whole insulin, insulin chains, or Aβ 1-40. We then took advantage of an observation that adding lipid to the enzyme significantly improved \textit{in vitro} cleavage of the Aβ FRET reporter (Figure 6C); the reason for this effect is unknown and could stem from stabilizing a more active form of purified SmSte24p, which was detergent-solubilized, or shifting the state of the substrate to a more readily cleaved conformer. Repeating the gel-based assay under conditions of added lipid revealed reduced levels of both Aβ 1-40 and insulin B-chain in the presence of protease (Figure 6D). Consistent with \textit{in vitro} competition experiments, we observed little if any reduction in the level of whole insulin under conditions of added lipid, whereas whole insulin was cleaved by IDE. Together, these findings indicate that non-prenylated peptides exhibiting strong competitive behavior are indeed cleaved by Ste24p.

\textbf{Mass spectroscopic analysis of Ste24p cleavage sites} - The cleavage sites recognized by Ste24p have been identified in various ways. For example, the distal cleavage site in a-factor was identified by N-terminal sequencing of an immunopurified a-factor intermediate (46). The CaaX cleavage sites of a-factor and prelamin A were both revealed by mass spectroscopy using purified components and model synthetic peptides (7,13). For both, cleavage occurred between the farnesylated cysteine and the a1 position of the CaaX motif, although the prelamin A peptide was predominantly cleaved between a1 and a2.

Despite its utility for monitoring protease activity, the readout of FRET-based methods does not include the precise sequence location(s) of cleavage, as cleavage occurring anywhere between the FRET pair will yield a positive signal. Moreover, cleavage outside the FRET pair can occur and not yield a signal. To precisely determine the Ste24p cleavage sites in three of the substrates investigated in this study, we used mass spectroscopy to analyze the proteolytic products generated by purified SmSte24p. The products derived from the K-Ras4b reporter were as predicted for CaaX proteolysis: cleavage between farnesylated cysteine and the a1 position of the CaaX motif (Figures 7D and 10). We next examined the products derived from the non-prenylated M16A reporter. This peptide was cleaved at a single site, between Gly and Val, near the C-terminus of the substrate (Figure 7). The analysis also revealed a minor impurity in the sample that was derived from inefficient peptide synthesis. The minor peptide lacks an Asn near the middle of the sequence. Nonetheless, this peptide was also cleaved at the same Gly-Val bond. Finally, analysis of products generated from insulin B-chain reveal two major cleavage sites near the middle of the peptide. Cleavage occurred between Tyr16 and Leu17 or between Leu17 and Val18 (Figures 7D and 11).

\textbf{DISCUSSION}  

The major finding of this study is the ability of Ste24p to cleave several non-prenylated oligopeptides \textit{in vitro}. In terms of specificity, we determined that Ste24p cleaves both the non-prenylated M16A reporter and farnesylated K-Ras4b reporter at a bond containing Val at the P1’ position (\textit{i.e.} X-Val). In these instances, the bond resides near the C-terminus (Figure 7D). This specificity may in part explain the ability of Ste24p to cleave the CVIA CaaX motif of the yeast a-factor precursor and a-factor CaaX mutants where Val has been substituted by other aliphatic residues (Ile, Leu) but generally not other types of amino acids (3,47,48). Curiously, the Gly-Val bond within the M16A reporter is cleaved \textit{in vivo} in the context of a-factor processing; the protease responsible is not believed to be Ste24p, although this conclusion should be revisited in light of our current findings (49). By comparison, insulin B-chain has two major \textit{in vitro} cleavage sites where P1’ is also an aliphatic amino acid (Leu or Val), but the bond is considerably farther from...
the C-terminus. The Aβ FRET reporter has aliphatic residues (i.e. Ala, Leu, Val) in the region between the FRET pair (LVFFAE) where Ste24p must be cleaving in order to yield a fluorescence signal. The known biological cleavage sites of Ste24p, in prelamin A (RSY-LLG) and α-factor (TAT-AAP), also bear aliphatic residues at the P1’ position (46,50). In vitro, purified Ste24p cleaves synthetic peptides based on the prelamin A C-terminus at multiple sites bearing a P1’ aliphatic residue (Gly, Ile, Leu, and to a lesser degree Met) (7). By contrast, Ste24p poorly cleaves after the farnesylated cysteine of the FRET peptide that we typically use to monitor Rce1p activity (Figure 1A) (34). This substrate has dinitrophenyl-lysine instead of Val at the P1’ position (i.e. a1 position of the CaaX motif). Moreover, Ste24p cannot cleave the prelamin A distal site when the P1’ position is mutated to Arg (RSY-RLG) (15). From these limited data, it appears that Ste24p prefers to cleave peptide bonds where P1’ is an aliphatic residue (i.e. Ala, Leu, Val), as long as other, yet to be identified, constraints are satisfied. We expect that this in vitro specificity will be preserved in vivo.

The anticipation of additional constraints for Ste24p is needed to explain why cleavage does not occur at all bonds containing a P1’ aliphatic. Additional constraints are observed for thermolysin, which cleaves substrates containing aliphatic or hydrophobic P1’ residues (Ala, Leu, Val, Ile, Met or Phe) unless P1 is an acidic residue (Asp, Glu) (51). Likewise, the bacterial Ste24p homolog, HtpX, cleaves a variety of non-prenylated substrates in vitro, including β-casein, SecY and itself (self cleavage), but it does not appear to cleave indiscriminately. The precise cleavage site preferences of HtpX have not been defined (52). Determining the specificity of promiscuous proteases can be difficult. For example, the site preferences of M16A proteases remain relatively undefined despite over 100 known cleavage sites (MEROPS peptidase database; https://merops.sanger.ac.uk/). Future investigations of Ste24p substrate interactions are likely to reveal the additional constraints on cleavage sites, which we predict will depend on conformational malleability around the cleaved bond. Ultimately, we predict that Ste24p will be found to cleave many substrates as has been commonly observed for M16A proteases and thermolysin.

The fact that Ste24p is not isoprenoid-dependent is clearly unusual for a protein canonically referred to as a CaaX-specific protease. By comparison, our evidence and data published elsewhere indicate that Rce1p is isoprenoid-dependent (9,40). Our findings further suggest that Ste24p has more biochemical similarity to M16A proteases than to Rce1p. While our initial experiments involving non-prenylated peptides were largely directed by the similarity of Ste24p and M16A protease structures (i.e. possession of voluminous internal cavities containing the active sites), we have now established that there are several non-prenylated substrates, including biological peptides, that can be cleaved by both proteases in vitro. M16A proteases use their β-sheet domain to properly position substrates for cleavage (i.e. a β-strand addition mechanism), so it is tempting to speculate that Ste24p uses its β-sheet domain in similar fashion (20,53). Consistent with this model is the observation that certain HIV inhibitors that inhibit Ste24p are known to be β-strand mimetics (e.g. ritonavir) (54,55). While Ste24p and M16A proteases can cleave common substrates in vitro (e.g. insulin B-chain; M16A reporter; α-factor precursor), these proteases cleave at different bond positions, indicating that the precise cleavage sites differ between the protease families (20). Additionally, the ability of insulin A- and B-chains to act as competitive substrates for Ste24 cleavage, while whole insulin cannot compete, hint that size and/or structural constraints differ between Ste24p and M16A proteases.

A critically unresolved issue about Ste24p relates to its biological function. Ste24p is referred to as a CaaX protease, and more specifically as a Type I CaaX protease in functional databases. But, evidence to date suggests that Rce1p is the more biologically relevant CaaX protease. For example, multiple CaaX proteins are recognized by Rce1p, while the only proteins recognized by Ste24p are precursors to α-factor and lamin A, and neither necessarily uses Ste24p exclusively for CaaX proteolysis (8-12,56). In additional support of Rce1p as the major CaaX protease, rce1−/− mice accumulate cleavable and methylatable substrates while ZmpSte24−/− mice do not (57). While Ste24p has the capacity to cleave certain CaaX proteins, we contend that its major biological functions lie elsewhere.

One intriguing potential role made possible by our observations is that Ste24p is generally involved in cleaving oligopeptides that have a high local concentration near or on the membrane in which Ste24p resides. These peptides would arise from normal protein turnover events that generate oligopeptides of varying length, hydrophobic character, and secondary structure predilection (e.g. farnesylated stubs of CaaX proteins; palmitoylated fragments, amyloidogenic peptides, etc.). Ste24p could be working in concert with M16A proteases in this manner. Ste24p would have primary responsibility for those that partition onto membranes and M16A proteases would
primarily cleave cytosolic oligopeptides. Our oligopeptidase model is fully compatible with observations about Ste24p and its interactions with hydrophobic α-factor, which is small enough to be captured within the Ste24p chamber, facilitating cleavage at multiple sites. For the larger prelamin A, we propose that Rce1p is mainly responsible for CaaX cleavage and that the oligopeptidase activity of Ste24p has been co-opted for cleavage at the prelamin A distal site during protein maturation, much like NF-κB and certain transcription factors use the proteasome for partial proteolysis and conversion to active forms (58-60).

Our model is also compatible with observations that Ste24p is involved in membrane protein quality control (61-63). It was recently reported that Ste24p is important for the clearance of a non-prenylated reporter protein that is stuck mid-translocation into the ER during signal recognition particle-independent protein translocation (63). While the exact role of Ste24p in this process remains unclear, it could be acting directly on the stuck polypeptide or as an oligopeptidase on peptide products derived by the action of other proteases more intimately involved in the extraction and clearance of the stuck polypeptide. Regardless, it is likely that Ste24p is one of several components that partner to efficiently clear the stuck polypeptide. Consistent with this model are strong genetic interactions between STE24 and CDC48 (an AAA ATPase involved in ER-associated degradation), Cdc48p-interactors (i.e. UBX2), and proteasome components (i.e. UBC7) (64-66).

Finally, we should also make clear that our model is not meant to suggest direct cleavage of insulin chains and Aβ 1-40 by Ste24p in vivo despite their cleavage in vitro. We do not expect these peptides to be primary substrates due to their differential localization relative to ER-localized Ste24p (insulin and Aβ are primarily extracellular). Identification of additional interacting substrates will certainly provide more clarity to the biological role of this enigmatic protease.

ACKNOWLEDGEMENTS

This work was supported by United States Public Health Services grant GM108612 (MCW) and the University of Georgia (UGA) (WKS). We are grateful to Dr. Dennis Phillips (PAMS facility, UGA) for mass spectrometry analysis, and Dr. Brandon Goblirsch (University of Virginia), Dr. Zachary Wood (UGA), Ben Boward (UGA), and members of the Schmidt Lab (UGA) for reagents and critical discussions that were instrumental to this study.

CONFLICT OF INTEREST

The authors declare that they have no conflicts of interest with the contents of this article.

AUTHOR CONTRIBUTIONS

ERH conceived and executed the majority of experiments, analyzed data, and drafted the original manuscript; BTA provided purified SmSte24p; MCW provided intellectual guidance on the project and helped revise the manuscript; WKS secured funding for the project, generally supervised the project, and edited the final copy of the manuscript.

All authors reviewed the manuscript and approved the final submitted version.

REFERENCES

1. Silvius, J. R. (2002) Mechanisms of Ras protein targeting in mammalian cells. *J. Membrane Biol.* **190**, 83-92
2. Tam, A., Nouvet, F., Fujimura-Kamada, K., Slunt, H., Sisodia, S. S., and Michaelis, S. (1998) Dual roles for Ste24p in yeast α-factor maturation: NH2-terminal proteolysis and COOH-terminal CaaX processing. *J. Cell Biol.* **142**, 635-649
3. Trueblood, C. E., Boyartchuk, V. L., Picologlou, E. A., Rozema, D., Poultet, C. D., and Rine, J. (2000) The CaaX proteases, Afc1p and Rce1p, have overlapping but distinct substrate specificities. *Mol. Cell. Biol.* **20**, 4381-4392
4. Plummer, L. J., Hildebrandt, E. R., Porter, S. B., Rogers, V. A., McCracken, J., and Schmidt, W. K. (2006) Mutational analysis of the Ras converting enzyme reveals a requirement for glutamate and histidine residues. *J Biol Chem* **281**, 4596-4605

5. Mokry, D. Z., Manandhar, S. P., Chicola, K. A., Santangelo, G. M., and Schmidt, W. K. (2009) Heterologous expression studies of *Saccharomyces cerevisiae* reveal two distinct trypanosomatid CaaX protease activities and identify their potential targets. *Eukaryot Cell* **8**, 1891-1900

6. Pryor, E., Horanyi, P., Clark, K., Fedoriw, N., Connelly, S., Koszelak-Rosenblum, M., Zhu, G., Malkowski, M., Wiener, M., and Dumont, M. (2013) Structure of the integral membrane protein CAAX protease Ste24p. *Science* **339**, 1600-1604

7. Quigley, A., Dong, Y., Pike, A., Dong, L., Shresta, L., Berridge, G., Stansfeld, P., Sansom, M., Edwards, A., Bountra, C., von Delft, F., Bullock, A., Burgess-Brown, N., and Carpenter, E. (2013) The structural basis of ZMPSTE24-dependent laminopathies. *Science* **339**, 1604-1607

8. Schmidt, W. K., Tam, A., Fujimura-Kamada, K., and Michaelis, S. (1998) Endoplasmic reticulum membrane localization of Rce1p and Ste24p, yeast proteases involved in carboxyl-terminal CAAX protein processing and amino-terminal a-factor cleavage. *Proc Natl Acad Sci USA* **95**, 11175-11180

9. Otto, J. C., Kim, E., Young, S. G., and Casey, P. J. (1999) Cloning and characterization of a mammalian prenyl protein-specific protease. *J. Biol. Chem.* **274**, 8379-8382

10. Bergo, M. O., Ambroziak, P., Gregory, C., George, A., Otto, J. C., Kim, E., Nagase, H., Casey, P. J., Balmain, A., and Young, S. G. (2002) Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. *Mol Cell Biol* **22**, 171-181

11. Roberts, P. J., Mitin, N., Keller, P. J., Chenette, E. J., Madigan, J. P., Currin, R. O., Cox, A. D., Wilson, O., Kirschmeier, P., and Der, C. J. (2008) Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification. *J Biol Chem* **283**, 25150-25163

12. Hanker, A. B., Mitin, N., Wilder, R. S., Henske, E. P., Tamanoi, F., Cox, A. D., and Der, C. J. (2010) Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling. *Oncogene* **29**, 380-391

13. Tam, A., Schmidt, W. K., and Michaelis, S. (2001) The multispans membrane protein Ste24p catalyzes CAAX proteolysis and NH2-terminal processing of the yeast a-factor precursor. *J Biol Chem* **276**, 46798-46806

14. Corrigan, D. P., Kuszczak, D., Rusinol, A. E., Thewke, D. P., Hrycyna, C. A., Michaelis, S., and Sinensky, M. S. (2005) Prelamin A endoproteolytic processing in vitro by recombinant Zmpste24. *Biochem J* **387**, 8379-8382

15. Barrowman, J., Hamblet, C., Kane, M. S., and Michaelis, S. (2012) Requirements for efficient proteolytic cleavage of prelamin A by ZMPSTE24. *PLoS One* **7**, e32120

16. Manolaridis, I., Kulkarni, K., Dodd, R. B., Ogasawara, S., Zhang, Z., Bineva, G., O'Reilly, N., Hanrahan, S. J., Thompson, A. J., Cronin, N., Iwata, S., and Barford, D. (2013) Mechanism of farnesylated CAAX protein processing by the intramembrane protease Rce1. *Nature* **504**, 301-305

17. Hildebrandt, E. R., Davis, D. M., Deaton, J., Krishnankutty, R. K., Lilla, E., and Schmidt, W. K. (2013) Topology of the yeast Ras converting enzyme as inferred from cysteine accessibility studies. *Biochemistry* **52**, 6601-6614

18. Erez, E., Fass, D., and Bibi, E. (2009) How intramembrane proteases bury hydrolytic reactions in the membrane. *Nature* **459**, 371-378

19. Wolfe, M. (2009) Intramembrane-cleaving Proteases. *Journal of Biological Chemistry* **284**, 13969-13973

20. Shen, Y., Joachimiak, A., Rosner, M. R., and Tang, W. J. (2006) Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. *Nature* **443**, 870-874

21. Im, H., Manolopoulou, M., Malito, E., Shen, Y., Zhao, J., Neant-Fery, M., Sun, C. Y., Meredith, S. C., Sisodia, S. S., Leissring, M. A., and Tang, W. J. (2007) Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. *J Biol Chem* **282**, 25453-25463

22. Kurochkin, I. V. (1998) Amyloidogenic determinant as a substrate recognition motif of insulin-degrading enzyme. *FEBS Lett* **427**, 153-156

23. Kurochkin, I. V. (2001) Insulin-degrading enzyme: embarking on amyloid destruction. *Trends in biochemical sciences* **26**, 421-425

24. Selkoe, D. J. (2001) Clearing the brain's amyloid cobwebs. *Neuron* **32**, 177-180

25. Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., and Guenette, S. (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-
protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100, 4162-4167

26. Leissring, M. A., Farris, W., Chang, A. Y., Walsh, D. M., Wu, X., Sun, X., Frosch, M. P., and Selkoe, D. J. (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087-1093

27. Alper, B., Rowse, J., and Schmidt, W. (2009) Yeast Ste23p shares functional similarities with mammalian insulin-degrading enzymes. Yeast 26, 595-610

28. Adames, N., Blundell, K., Ashby, M. N., and Boone, C. (1995) Role of yeast insulin-degrading enzyme homologs in propheromone processing and bud site selection. Science 270, 464-467

29. Barrowman, J., Wiley, P. A., Hudon-Miller, S. E., Hrycyna, C. A., and Michaelis, S. (2012) Human ZMPSTE24 disease mutations: residual proteolytic activity correlates with disease severity. Hum Mol Genet 21, 4084-4093

30. Ricardo, S., and Lehmann, R. (2009) An ABC transporter controls export of a Drosophila germ cell attractant. Science 323, 943-946

31. Adolphsen, K., Amell, A., Havko, N., Kevorkian, S., Mears, K., Neher, H., Schwarz, D., and Schulze, S. R. (2012) Type-I prenyl protease function is required in the male germline of Drosophila melanogaster. G3 2, 629-642

32. Fujimura-Kamada, K., Nouvet, F. J., and Michaelis, S. (1997) A novel membrane-associated metalloprotease, Ste24p, is required for the first step of NH2-terminal processing of the yeast a-factor precursor. J. Cell Biol. 136, 271-285

33. Ghaemmaghami, S., Huh, W. K., Bower, K., Belle, A., Dephoure, N., O'Shea, E. K., and Weissman, J. S. (2003) Global analysis of protein expression in yeast. Nature 425, 737-741

34. Porter, S. B., Hildebrandt, E. R., Breevoort, S. R., Mokry, D. Z., Dore, T. M., and Schmidt, W. K. (2007) Inhibition of the CaaX proteases Rce1p and Ste24p by peptidyl (acyloxy)methyl ketones. Biochim Biophys Acta 1773, 853-862

35. Kukday, S. S., Manandhar, S. P., Ludley, M. C., Burriss, M. E., Alper, B. J., and Schmidt, W. K. (2012) Cell-permeable, small-molecule activators of the insulin-degrading enzyme. J Biomol Screen 17, 1348-1361

36. Sikorski, R. S., and Hieter, P. (1989) A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122, 19-27

37. Oldenburg, K. R., Vo, K. T., Michaelis, S., and Paddon, C. (1997) Recombination-mediated PCR-directed plasmid construction in vivo in yeast. Nucleic Acids Res 25, 451-452

38. Alper, B., and Schmidt, W. (2009) A capillary electrophoresis method for evaluation of Aβ proteolysis in vitro. Journal of Neuroscience Methods 178, 40-45

39. Schmidt, W. K., Tam, A., and Michaelis, S. (2000) Reconstitution of the Ste24p-dependent N-terminal proteolytic step in yeast a-factor biogenesis. J. Biol. Chem. 275, 6227-6233

40. Hollander, I., Frommer, E., and Mallon, R. (2000) Human ras-converting enzyme (hRCE1) endoproteolytic activity on K-ras-derived peptides. Anal Biochem 286, 129-137

41. Manandhar, S. P., Hildebrandt, E. R., and Schmidt, W. K. (2007) Small-molecule inhibitors of the Rce1p CaaX protease. J Biomol Screen 12, 983-993

42. Lazure, C., Gauthier, D., Jean, F., Boudreault, A., Seidah, N. G., Bennett, H. P., and Hendy, G. N. (1998) In vitro cleavage of internally quenched fluorogenic human parathyroid hormone and parathyroid-related peptide substrates by furin. Generation of a potent inhibitor. J Biol Chem 273, 8572-8580

43. Guo, Q., Manolopoulou, M., Bian, Y., Schilling, A. B., and Tang, W. J. (2010) Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme. J Mol Biol 395, 430-443

44. McLure, J. A., Miners, J. O., and Birkett, D. J. (2000) Nonspecific binding of drugs to human liver microsomes. British journal of clinical pharmacology 49, 453-461

45. Mukherjee, A., Song, E., Kihiko-Ehmann, M., Goodman, J. P., Jr., Pyrek, J. S., Estus, S., and Hersh, L. B. (2000) Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J Neurosci 20, 8745-8749

46. Chen, P., Sapperstein, S. K., Choi, J. D., and Michaelis, S. (1997) Biogenesis of the Saccharomyces cerevisiae mating pheromone a-factor. J Cell Biol 136, 251-269

47. Boyartchuk, V. L., and Rine, J. (1998) Roles of prenyl protein proteases in maturation of Saccharomyces cerevisiae a-factor. Genetics 150, 95-101
48. Krishnakutty, R. K., Kukday, S. S., Castleberry, A. J., Breevoort, S. R., and Schmidt, W. K. (2009) Proteolytic processing of certain CaaX motifs can occur in the absence of the Rce1p and Ste24p CaaX proteases. *Yeast* **26**, 451-463.

49. Chen, P., Choi, J. D., Wang, R., Cotter, R. J., and Michaelis, S. (1997) A novel α-factor-related peptide of *Saccharomyces cerevisiae* that exits the cell by a Ste6p-independent mechanism. *Mol. Biol. Cell* **8**, 1273-1291.

50. Weber, K., Plessmann, U., and Traub, P. (1989) Maturation of nuclear lamin A involves a specific carboxy-terminal trimming, which removes the polyisoprenylation site from the precursor; implications for the structure of the nuclear lamina. *FEBS Letters* **257**, 411-414.

51. Keil, B. (1992) *Specificity of Proteolysis*, Springer-Verlag.

52. Sakoh, M., Ito, K., and Akiyama, Y. (2005) Proteolytic activity of HtpX, a membrane-bound and stress-controlled protease from *Escherichia coli*. *Mol. Biol. Cell* **8**, 1273-1291.

53. Remaut, H., and Waksman, G. (2006) Protein-protein interaction through β-strand addition. *Trends in biochemical sciences* **31**, 436-444.

54. Loughlin, W. A., Tyndall, J. D., Glenn, M. P., and Fairlie, D. P. (2004) β-strand mimetics. *Chem Rev* **104**, 6085-6117.

55. Loughlin, W. A., Tyndall, J. D., Glenn, M. P., Hill, T. A., and Fairlie, D. P. (2010) Update 1 of: β-strand mimetics. *Chem Rev* **110**, PR32-69.

56. Boyartchuk, V. L., Ashby, M. N., and Rine, J. (1997) Modulation of Ras and α-factor function by carboxy-terminal proteolysis. *Science* **275**, 1796-1800.

57. Leung, G. K., Schmidt, W. K., Bergo, M. O., Gavino, B., Wong, D. H., Tam, A., Ashby, M. N., Michaelis, S., and Young, S. G. (2001) Biochemical studies of *Zmpste24*-deficient mice. *J Biol Chem* **276**, 29051-29058.

58. Hoppe, T., Matuschewski, K., Rape, M., Schlenker, S., Ulrich, H. D., and Jentsch, S. (2000) Activation of a membrane-bound transcription factor by regulated ubiquitin/proteasome-dependent processing. *Cell* **102**, 577-586.

59. Rape, M., and Jentsch, S. (2002) Taking a bite: proteasomal protein processing. *Nature cell biology* **4**, E113-116.

60. Skaug, B., Jiang, X., and Chen, Z. J. (2009) The role of ubiquitin in NF-kappaB regulatory pathways. *Annual review of biochemistry* **78**, 769-796.

61. Ast, T., Michaelis, S., and Schuldiner, M. (2016) The Protease Ste24 Clears Clogged Translocons. *Cell* **164**, 103-114.

62. Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E. D., Sevier, C. S., Ding, H., Koh, J. L., Toufighi, K., Mostafavi, S., Prinz, J., St Onge, R. P., VanderSluis, B., Makhnevych, T., Vizeacoumar, F. J., Alizadeh, S., Bahr, S., Brost, R. L., Chen, Y., Cokol, M., Deshpande, R., Li, Z., Lin, Z. Y., Liang, W., Marbach, M., Paw, J., San Luis, B. J., Shuteriqi, E., Tong, A. H., van Dyk, N., Wallace, I. M., Whitney, J. A., Weirauch, M. T., Zhong, G., Zhu, H., Houry, W. A., Brudno, M., Ragibizadeh, S., Papp, B., Pal, C., Roth, F. P., Giaever, G., Nislow, C., Troyanskaya, O. G., Bussey, H., Bader, G. D., Gingras, A. C., Morris, Q. D., Kim, P. M., Kaiser, C. A., Myers, C. L., Andrews, B. J., and Boone, C. (2010) The genetic landscape of a cell. *Science* **327**, 425-431.

63. Anderegg, R., Betz, R., Carr, S., Crabbe, J., and Duntze, W. (1988) Structure of *Saccharomyces cerevisiae* mating hormone α-factor: identification of S-farnesyl cysteine as a structural component. *J. Biol. Chem.* **263**, 18236-18240.
FOOTNOTES

3 The abbreviations used are: ABZ (amino-benzoic acid); E^EDANS, EDANS-L-glutamate; IDE, insulin-degrading enzyme or insulysin; K^D, ε-dinitrophenyl-lysine; K^DABCYL, ε-DABCYL-L-lysine; Y^NITRO, 3-nitro-L-tyrosine.

4 Hildebrandt and Schmidt, unpublished observations.

FIGURE LEGENDS

Figure 1. Ste24p-mediated cleavage of a farnesylated substrate is competed by non-prenylated peptides. A) Sequences of farnesylated and non-prenylated peptides used in this experiment. Optimal Rce1p and Ste24p activities require differential placement of the quenching group (34). ABZ (amino-benzoic acid); K^D (ε-dinitrophenyl-lysine). B) Time course activity profiles of Rce1p (top) and Ste24p (bottom) measured in relative fluorescence units (rfu) in the presence of methanol or competitor (2-fold molar excess); the farnesylated substrates are as described in panel A. Initial linear velocities were used to calculate % activity relative to the methanol condition. C) The indicated enzyme activities were calculated for activity against the appropriate farnesylated substrate in the absence or presence of competing peptides. Bars represent the average of values from duplicate samples within this single experiment; error bars represent the range. Similar results were observed in five independent iterations of the experiment having subtle variations in the experimental setup (e.g. different molar ratios of substrate:competitor; different membrane preps of protease activity, etc.). The yeast membranes used as the source of protease activity were derived from SM3614 transformed with either pWS479 (RCE1) or pSM1282 (STE24).

Figure 2. Ste24p-mediated cleavage of an M16A protease substrate. A) Sequence of M16A reporter. ABZ (amino-benzoic acid); Y^NITRO (3-nitrotyrosine). B) The indicated enzyme activities were assayed for activity against a non-prenylated M16A protease substrate. Bars represent the average values of multiple replicates (n=7) from two independent experiments; error bars represent the standard deviation. All enzyme components (i.e. membranes enriched for Rce1p or Ste24p; recombinant IDE) were used at 0.25 mg/ml final concentration. C) The activity of Ste24p against the M16A reporter in the absence or presence of competing peptides as described for Figure 1. The membranes used as the source of Rce1p and Ste24p protease activities were derived as described for Figure 1. Purified rat IDE was isolated as previously described (38). Bars represent the average values of multiple replicates (n=5) from two independent experiments; error bars represent the standard deviation.

Figure 3. Enzyme Kinetics. A-B) Yeast membranes containing Ste24p were assayed for activity against the indicated farnesylated (A) or non-prenylated peptide (B) over a range of concentrations. C) Activity of purified rat IDE against the non-prenylated peptide described for panel B. Solid lines represent curve fitting using an allosteric-sigmoidal model. Dashed lines represent the data fit to a Michaelis-Menten model. Insets are magnified parts of the curve at the lowest concentrations evaluated. Each graph is representative of multiple independent experiments: panel A (n=5); panel B (n=2); panel C (n=1; also see (35)). The kinetic parameters associated with each panel were derived using Prism 6 for the representative data set; standard errors shown represent error with respect to curve fitting. D) Activity of membrane-associated Rce1p and Ste24p in the presence of increasing amounts of trans,trans-farnesyl bromide. The farnesylated substrates are as described in Figure 1A. The graph is representative of two independent experiments; error bars represent the range from duplicate samples within a single experiment.

Figure 4. Impact of membrane concentration on Ste24p activity. Yeast membranes containing Ste24p were assayed for activity against a farnesylated (open circle) or non-prenylated peptide (closed square) in the presence of increasing amounts of yeast membranes devoid of Ste24p activity. The source of Ste24p activity was derived as previously described for Figure 1. The membranes devoid of Ste24p activity were derived from SM3614 transformed with pRS316 (CEN URA3). The data points plotted represent the average value from several independent experiments (n=5, farnesylated; n=4, non-prenylated); error bars represent the standard deviations. Curve fitting was either linear (non-prenylated) or exponential (farnesylated).
Figure 5. **Ste24p cleaves an Aβ 1-28 based peptide.** A) Sequence of Aβ 1-28 based substrate. K^DABCYL (4-(4-dimethylaminophenylazo)benzoyl-L-lysine); E^EDANS (L-glutamic acid-γ-[2-(1-sulfonyl-5-naphthyl)-aminoethylamide]). B) The indicated enzyme activities were observed using the Aβ 1-28 substrate. The graph is representative of two independent experiments. Bars represent the average values of multiple replicates (n=5); error bars represent the standard deviation. The sources of enzyme activities were derived as previously described for Figure 2. Membranes containing human Rce1p or Ste24p were derived from SM3614 transformed with either pWS335 (HsRCE1) or pWS1275 (HsSTE24). C) The kinetic curve was determined as described for Figure 3 using the Aβ 1-28 substrate and membranes containing ScSte24p. Curve fitting to the data using an allosteric-sigmoidal model and a Michaelis-Menten model gave nearly identical results. The kinetic parameters were derived using Prism 6; standard errors shown represent error with respect to curve fitting.

Figure 6. **Evaluation of Ste24p activity against biological peptides.** A) Competition assays were performed using the indicated protease and appropriate FRET substrate in the absence or presence of insulin. Refer to Figure 1A for Rce1p and Ste24p substrates and Figure 2A for the IDE substrate. Substrates were used at 10 µM and competing peptide at 40 µM. D – DMSO; Ins – whole insulin. B) Competition assays were performed as described for panel A using Ste24p membranes and the indicated insulin species. DTT/IA indicates pretreatment of the competitor with 3-fold molar excess diithiothreitol (DTT), followed by 6 fold-molar excess iodoacetamide (IA). This serves to dissociate insulin A and B-chains and block reformation of disulfide bonds. D – DMSO; A Ins – carboxymethylated insulin A-chain; B Ins – carboxymethylated insulin B-chain; Ins – whole insulin. The graphs for panels A and B are representative of multiple independent experiments (3 in each case). The specific graphs represent the averaged value of replicates (n=2) from a single experiment where the DMSO-treated control was set to 100% activity; error bars represent the range. C) Purified SmSte24p (0.8 µM) was incubated with the Aβ 1-28 FRET reporter (50 µM) in the absence and presence of E. coli lipid. 1x = 125 µg/ml total E. coli lipid. rfu/min is relative fluorescence units per minute. The graph is representative of 5 independent tests of lipid effects on this enzyme/substrate combination. D) SDS-PAGE analysis of products derived from incubation of purified SmSte24p or rat IDE with indicated substrates in the presence of E. coli lipid. The gels are representative of five independent experiments. The concentrations of enzymes, substrates, and lipids used are described in the Experimental Procedures section.

Figure 7. **Mass spectroscopic analysis of Ste24p cleavage products.** A-B) Mass spectra of the M16A reporter in the absence (A) and presence of purified SmSte24p (B). C) The peaks identified in panels A and B correspond to the indicated species. Peptide 3 is a minor contaminating peptide that lacks the Asn residue present in peptide 1. D) Analysis of mass spectra (see Figures 10 and 11) reveals cleavage sites in the indicated reporter substrates. Triangles mark major cleavage sites that were identified.

Figure 8. **Structural views of MmRce1, SmSte24p, RnIDE, and BtThermolysin.** A) Cut-away views reveal the groove of MmRce1p, chambers of SmSte24p and RnIDE, and globular structure of BtThermolysin. The structures were created using Pymol from PDB files 4CAD, 4IL3, 2JG4, and 1LND. B) Structure surrounding active sites of MmRce1, SmSte24p, RnIDE, and BtThermolysin. The active sites of the metalloproteases were oriented similarly to showcase the active site Zn⁵⁺ co-factor (orange), Zn⁵⁺-chelating residues (green), and nearby b-strand platform (magenta). The structures were created using Pymol from PDB files 4CAD (residues 138-179, 200-215, 218-236), 4IL3 (223-227, 248-254, 274-280, 263-268, 295-305, 386-394), 2JG4 (83-94, 106-115, 135-155, 185-193, 253-261), and 1LND (37-47, 98-124, 140-148, 163-170).

Figure 9. **Correlation between fluorescence and peptide concentration.** Peptides used in kinetic studies are indicated at the top of each column of corresponding calibration curves. Top row of graphs: Effect of intermolecular quenching on fluorescence. Fluorescence output (relative fluorescence units, RFU) was independently measured for free ABZ (A-B) and EDANS (C) and a 1:1 molar mixture of K^DABCYL and ABZ (A), Y^NITRO and ABZ (B), and DABCYL and EDANS (C) in HM buffer. Middle row of graphs: The ratio between unquenched and (intermolecular) quenched fluorescence was graphed as a function of concentration. The data were fit to a polynomial equation, which was used to calculate a correction factor at any particular substrate concentration. The correction factor was multiplied by the raw fluorescence data to obtain a normalized fluorescence value. Bottom row of graphs: Relationship between fluorescence of ABZ (A and B used same graph) and EDANS (C) vs. concentration of fluorophore. The data were fit to a polynomial equation that was used to
convert normalized fluorescence values to µM values.

Figure 10. Mass spectra of products derived from the K-Ras4b reporter treated with purified SmSte24p. A-C) Samples of K-Ras4b reporter incubated in the absence (A) and presence of purified SmSte24p (B-C) were analyzed by LC-MS using a Bruker Esquire 3000 Plus mass spectrometer. The sequences and theoretical masses that correspond to identified peaks are shown centered or adjacent to appropriate peaks. One of the prenylated species in panel A lacking ABZ and N-terminal Lys (SKTKC(f)VIK\(^D\)) is likely a minor impurity from peptide synthesis. Spectra for panels B and C were derived from different LC fractions corresponding to 19.7-20 min and 20.2-20.4 min, respectively. D-E) The non-prenylated species detected in panel A were not present in mass spectra provided by the peptide manufacturer; they are likely a byproduct of ionization (67). In support of this, we observed that MS/MS analysis of the double ion form of the uncleaved farnesylated peptide (762.4 m/z) resulted in loss of farnesylated peptide ions (MH\(^+\) 1523.9 m/z; MH\(^{2+}\) 762.4 m/z) (D) and appearance of non-prenylated peptide ions (MH\(^+\) 1319.8 m/z; MH\(^{2+}\) 660.4 m/z) (E).

Figure 11. Mass spectra of products derived from insulin B-chain treated with purified SmSte24p. Spectra of carboxymethylated insulin B-chain in the absence (A) and presence of SmSte24p (B) were analyzed by LC-MS using a Bruker Esquire 3000 Plus mass spectrometer. The amino acid ranges of insulin B-chain and corresponding theoretical monoisotopic masses are shown centered or adjacent to appropriate peaks. Spectra for panels A and B were derived from different LC fractions corresponding to 20.5-20.6 min and 17.8-18.0 min, respectively. Peaks for products corresponding to amino acids 1-17 were observed in other LC fractions but are not shown. For the few instances where the theoretical mass did not exactly match the major peak detected, magnification of the peak region to increase resolution revealed the theoretical mass as part of an isotopic set. As examples, magnification of spectra centered on 823.9 m/z and 945.4 m/z (B) revealed monoisotopic peaks nearly identical to theoretical masses of 823.4 m/z (C) and 944.5 m/z (D), respectively.

TABLES

Table 1. Kinetics of Ste24p cleavage of K-Ras4b reporter in the presence of increasing concentrations of insulin B-chain. All reaction conditions were the same as described for Figure 3A. Data shown represents one of two biological replicates. Similar values and trends for \(K_M\) and \(V_{max}\) parameters were observed in both experiments. Standard errors shown represent error with respect to curve fitting using Prism 6.

|                | 0 µM       | 10 µM      | 20 µM      | 33 µM      |
|----------------|------------|------------|------------|------------|
| \(K_M\) (µM)  | 23.2 ± 0.8 | 29.7 ± 1.2 | 37.5 ± 2.8 | 37.5 ± 2.3 |
| \(V_{max}\) (µM/min) | 0.56 ± 0.01 | 0.52 ± 0.02 | 0.56 ± 0.03 | 0.46 ± 0.02 |
| Hill coefficient | 2.04 ± 0.13 | 2.49 ± 0.20 | 2.16 ± 0.21 | 2.38 ± 0.23 |
Figure 1. Hildebrandt et al

A

**substrates**
- Rce1p: ABZ-KSKTKCK\text{ch3}IM
- Ste24p: ABZ-KSKTKCVIK\text{ch3}

**competitors**
- C(f)VIA: YIIKGVFWDPACVIA
- a-factor: YIIKGVFWDPAC
- CVIA: YIIKGVFWDPACVIA

B

- MeOH
- C(f)VIA
- a-factor
- CVIA

C

| % activity | MeOH | C(f)VIA | a-factor | CVIA |
|------------|------|---------|----------|------|
| 100        | 100  | 36      | 83       | 90   |

rfu

| time, min | 0    | 30   | 60   |
|-----------|------|------|------|
| Rce1p     | 1000 | 1400 | 1800 |
| Ste24p    | 1000 | 1400 | 1800 |

Downloaded from http://www.jbc.org/ by guest on June 21, 2016
Figure 2. Hildebrandt et al

A

ABZ-SEKKDNYIIKGVYNITRO

B

μM/min

0.3

0.2

0.1

0.0

vector Rce1p Ste24p IDE

C

% Ste24p activity

100

50

0

MeOH C(f)VIA θ-factor CVIA
Figure 3. Hildebrandt et al

\[ \begin{align*}
\text{A} &: \quad \text{ABZ-KSKTKCVIK}^D \\
\text{B} &: \quad \text{ABZ-SEKKDNYIIKGVY}^{\text{NITRO}} \\
\text{C} &: \quad \text{ABZ-SEKKDNYIIKGVY}^{\text{NITRO}} \text{ IDE} \\
\text{D} &: \quad \text{Rce1p} \quad \text{Ste24p}
\end{align*} \]

- A: \( \text{K}_M (\mu\text{M}) = 16.4 \pm 1.0 \)
- B: \( \text{K}_M (\mu\text{M}) = 112.5 \pm 6.4 \)
- C: \( \text{K}_M (\mu\text{M}) = 192.2 \pm 51.0 \)
- D: \( \text{K}_M (\mu\text{M}) = 192.2 \pm 51.0 \)

- A: \( \text{V}_\text{max} (\mu\text{M/min}) = 0.53 \pm 0.01 \)
- B: \( \text{V}_\text{max} (\mu\text{M/min}) = 1.66 \pm 0.04 \)
- C: \( \text{V}_\text{max} (\mu\text{M/min}) = 1.92 \pm 0.28 \)
- D: \( \text{V}_\text{max} (\mu\text{M/min}) = 1.92 \pm 0.28 \)

- A: \( \text{Hill} = 1.79 \pm 0.16 \)
- B: \( \text{Hill} = 1.17 \pm 0.03 \)
- C: \( \text{Hill} = 1.17 \pm 0.11 \)
- D: \( \text{Hill} = 1.17 \pm 0.11 \)
Figure 4. Hildebrandt et al.
**Figure 5. Hildebrandt et al.**

A. **DAEFRHSGYEHQQK**

B. 

|        | vector | Rce1p | Ste24p | IDE  | Hs   | Hs  |
|--------|--------|-------|--------|------|------|-----|
| μM/min | 0.000  | 0.004 | 0.008  | 0.012| 0.004|     |

C. 

- **Kₘ (μM)**: 52.3 ± 9.1
- **Vₘₐₓ (μM/min)**: 0.036 ± 0.006
- **Hill**: 1.02 ± 0.23
Figure 6. Hildebrandt et al

A

% activity

Rce1p  Ste24p  IDE

D  A  Ins  B  Ins  Ins  D  D  Ins

B

% activity

D  A  Ins  B  Ins  Ins  D  Ins

C

μM/min

-  4x  -  +  +  +  +

D  +  +  +

SmSte24p  +  +  +

rat IDE  -  +  -

proteases >

D  +  +  +

Ste24p  -  +  -

Ins  -  -  +

Ins  -  -  +

Aβ1-40
Figure 7. Hildebrandt et al

A

B

C

| Peptide                              | MH⁺     |
|--------------------------------------|---------|
| ABZ-SEKKDNYIIKGVY₅¹¹⁹⁰¹⁰      | 1720.85 |
| ABZ-SEKKDNYIIG              | 1413.74 |
| ABZ-SEKKDYIIKGVY₅¹¹⁹⁰¹⁰      | 1606.81 |
| ABZ-SEKKDYIIG              | 1299.69 |

D

M16A reporter

K-Ras4b reporter

insulin B-chain

FVNQHLCSHLVEALYLVCGERGFFYTPKA
Figure 8, Hildebrandt et al.
Figure 9, Hildebrandt et al.

A

\[ \text{ABZ-KS\textsuperscript{D}TKCVIK} \]

- \[ \text{ABZ} \]
- \[ \text{K\textsuperscript{D} + ABZ} \]

RFU vs. [ABZ] or [K\textsuperscript{D} + ABZ] µM

\[ y = 4E-06x^2 + 0.0049x + 1 \]
\[ R^2 = 0.99892 \]

RFU ratio (ABZ/K\textsuperscript{D} + ABZ) vs. µM

B

\[ \text{ABZ-SE\textsuperscript{K}KDN\textsuperscript{Y}IIGVY\textsuperscript{NITRO}} \]

- \[ \text{ABZ} \]
- \[ \text{YNITRO + ABZ} \]

RFU vs. [ABZ] or [YNITRO + ABZ] µM

\[ y = 4E-07x^2 + 0.0019x + 1 \]
\[ R^2 = 0.99523 \]

RFU ratio (ABZ/YNITRO + ABZ) vs. µM

C

\[ \text{DAEFRHDGYYEVHHQ-K\textsuperscript{DABCYLL}VFAE\textsuperscript{EDANS}DVGSNK} \]

- \[ \text{EDANS} \]
- \[ \text{DABCYL + EDANS} \]

RFU vs. [EDANS] or [DABCYL + EDANS] µM

\[ y = 4E-07x^2 + 0.0114x + 1 \]
\[ R^2 = 0.99758 \]

RFU ratio (EDANS/DABCYL + EDANS) vs. µM

y = 7E-07x^2 + 0.0115x
\[ R^2 = 0.99928 \]
Figure 10, Hildebrandt et al.
Figure 10, Hildebrandt et al. (continued)
Figure 11, Hildebrandt et al.

A. insulin B-chain

- (1-30) $\text{MH}_3^+$ 1172.2
- (1-30) $\text{MH}_4^+$ 879.4

B. insulin B-chain + SmSte24p

- (17-30) $\text{MH}_2^{2+}$ 823.4
- (18-30) $\text{MH}_3^{2+}$ 766.9

C. (17-30) $\text{MH}_2^{2+}$ 823.4

D. (1-16) $\text{MH}_2^{2+}$ 944.5
Ste24p Mediates Proteolysis of both Isoprenylated and Non-prenylated Oligopeptides
Emily R. Hildebrandt, Buenafe T. Arachea, Michael C. Wiener and Walter K. Schmidt
J. Biol. Chem. published online April 29, 2016

Access the most updated version of this article at doi: 10.1074/jbc.M116.718197

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 0 references, 0 of which can be accessed free at http://www.jbc.org/content/early/2016/04/29/jbc.M116.718197.full.html#ref-list-1